Latest News

Takeda announces discontinuation of the phase 3 clinical trial TOURMALINE-AL1 in AL amyloidosis

  The pharmaceutical company Takeda announced that the Phase 3 TOURMALINE-AL1 clinical trial in patients with relapsed or refractory AL amyloidosis did not meet the first of two primary endpoints. Treatment with ixazomib in combination with dexamethasone did not demonstrate a significant improvement in overall hematologic response compared to physician’s choice of standard of care…

Read more

ASH 2018 highlights in myeloma

Myeloma Patients Europe held a webinar to review the most recent myeloma findings presented at the annual meeting of the American Society of Hematology (ASH) that took place in San Diego (California, United States) in December 2018.

Read more

September 2026

MO
TU
WE
TH
FR
SA
SU
31
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
1
2
3
4
Events for 1st September
No Events
Events for 2nd September
No Events
Events for 3rd September
No Events
Events for 4th September
No Events
Events for 5th September
No Events
Events for 6th September
No Events
Events for 7th September
No Events
Events for 8th September
No Events
Events for 9th September
No Events
Events for 10th September
No Events
Events for 11th September
No Events
Events for 12th September
No Events
Events for 13th September
No Events
Events for 14th September
No Events
Events for 15th September
No Events
Events for 16th September
No Events
Events for 17th September
No Events
Events for 18th September
No Events
Events for 19th September
No Events
Events for 20th September
No Events
Events for 21st September
No Events
Events for 22nd September
No Events
Events for 23rd September
No Events
Events for 24th September
No Events
Events for 25th September
No Events
Events for 26th September
No Events
Events for 27th September
No Events
Events for 28th September
No Events
Events for 29th September
No Events
Events for 30th September
No Events